Allotexfounded In 2014 By Drdavid Mullerspecializes In Developing Human Allograft Inlays And Onlaysthe Company Aims To Improve Biocompatibility In Ophthalmic Applicationsparticularly Addressing Limitations In Synthetic Corneal Inlay Technologyallotex Has Filed Multiple Patents Related To Corneal Implant Systems And Methodsshowcasing Its Commitment To Innovation In The Field Of Ophthalmology In Addition To Its Work In Ophthalmologysome Sources Indicate That Allotex May Also Be Involved In The Dental Industryfocusing On Allograft Solutions For Oral Tissue Repair And Restorationthe Company Is Headquartered In Bostonmassachusettswith Research And Development Facilities In Zurichswitzerlandallotex Has Successfully Raised $46 75 Million In Funding And Is In The Series B Ii Stage
